SCHEMBL5650557

SCHEMBL5650557

CCNC(=O)COc1ccc(Cl)cc1CNC(=O)Cc1c(C)ccn(NCc2ccccc2N2CCOCC2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
F2 P00734 4/20 0.45
PRSS1 P07477 4/20 0.45
PRSS2 P07478 4/20 0.45
PRSS3 P35030 4/20 0.45
ANO1 Q5XXA6 1/20 0.41
ANO2 Q9NQ90 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647344 0.90 F2 (0.45) TSHRLMNASMN1; SMN2NPC1MAPT
SCHEMBL5651637 0.86 F2 (0.46) TSHRLMNASMN1; SMN2NPC1MAPT
SCHEMBL5649545 0.86 F2 (0.48) TSHRLMNASMN1; SMN2NPC1MAPT
SCHEMBL5651509 0.85 F2 (0.54) SMN1; SMN2MAPTF2PRSS1PRSS2
SCHEMBL5650131 0.84 F2 (0.52) LMNASMN1; SMN2F2PRSS1PRSS2
SCHEMBL5648295 0.84 ANO1 (0.48) LMNAMAPTF2PRSS1PRSS2
SCHEMBL5645845 0.82 F2 (0.48) LMNASMN1; SMN2MAPK1F2PRSS1
SCHEMBL5650277 0.82 F2 (0.51) SMN1; SMN2NPC1F2PRSS1PRSS2
SCHEMBL5651304 0.82 F2 (0.50) LMNASMN1; SMN2F2PRSS1PRSS2
SCHEMBL5654097 0.82 F2 (0.60) LMNAMAPTF2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161643-A1 Pyridin-2-one compounds useful as inhibitors of thrombin ASTRAZENECA AB (SE) 2007-07-12 US disclosed
EP-1713774-A1 NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN AstraZeneca AB (SE) 2006-10-25 EP disclosed
WO-2005075424-A1 NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN ASTRAZENECA AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161643-A1 Pyridin-2-one compounds useful as inhibitors of thrombin PLG, F2, PLAT TSHR 398/4885LMNA 287/4885SMN1; SMN2 3414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.